Welcome to our dedicated page for Guardian Pharmacy Services news (Ticker: GRDN), a resource for investors and traders seeking the latest updates and insights on Guardian Pharmacy Services stock.
Guardian Pharmacy Services, Inc. provides long-term care pharmacy services for residents of long-term health care facilities. The company partners with LTCFs through a locally based pharmacy model to dispense medications and deliver technology-enabled clinical and administration services intended to support drug-regimen adherence and reduce medication-administration errors.
Recurring GRDN news covers quarterly results and guidance, resident and prescription-volume trends, the effects of drug-pricing changes, healthcare conference presentations, and capital-structure activity involving Class A common stock. Company updates also reference its pharmacy network, facility relationships, and service categories across assisted living, behavioral health, group home, and other long-term care settings.
Guardian Pharmacy Services (NYSE: GRDN) will release its second quarter 2026 financial results after market close on Thursday, August 6, 2026. Management will discuss the results on a conference call at 4:30 p.m. Eastern Time, accessible via audio webcast and dedicated phone lines for U.S., Canada, and international participants.
A webcast replay will be available shortly after the call’s completion through the company’s investor relations website.
Guardian Pharmacy Services (NYSE: GRDN) announced the acquisition of Wellness Concepts, an LTC pharmacy in Grottoes, Virginia. This expands Guardian’s Virginia footprint to three pharmacies in Gainesville, Wytheville, and Grottoes.
Wellness Concepts keeps its leadership and staff, while gaining Guardian’s national clinical, operational, and technology support.
Guardian Pharmacy Services (NYSE: GRDN) announced leadership transitions effective July 1, 2026. Long-time Executive Vice President of Sales & Operations Kendall Forbes will retire. David Morris, currently EVP and CFO, becomes Chief Operating Officer, and Will Mudd, Senior Vice President, Finance, is appointed Chief Financial Officer.
Guardian highlights internal succession, leadership depth, and its focus on developing talent from within as it continues to grow.
Guardian Pharmacy Services (NYSE: GRDN) reported Q1 2026 results: revenue $336.6M (+2% YoY), net income $13.5M, adjusted EBITDA $29.8M, and diluted EPS $0.21. Cash was $64.9M with no long-term debt under the credit facility. Residents served rose to ~207,000 (+10% YoY). Updated FY2026 guidance: revenue $1.40B–$1.42B, adjusted EBITDA $123M–$127M. Company completed a non-dilutive secondary offering increasing public float and filed a new shelf registration; no proceeds retained and no change to outstanding Class A shares.
Guardian Pharmacy Services (NYSE: GRDN) will participate in the Bank of America 2026 Healthcare Conference in Las Vegas on Wednesday, May 13, 2026. Fred Burke, President and CEO, will take part in a 9:20 a.m. PDT fireside chat. A live audio webcast will be available via the company's investor website.
Guardian Pharmacy Services (NYSE: GRDN) will release first quarter 2026 financial results after market close on Wednesday, May 6, 2026. Management will host a conference call at 4:30 p.m. ET to discuss results.
The call will stream via audio webcast at the company's investor site and is reachable by U.S./Canada dial-in +1 (833) 461-5787, international +1 (585) 542-9983, conference ID 621845633. A replay will be available shortly after the call.
Guardian Pharmacy Services (NYSE: GRDN) priced an upsized underwritten public offering of 6,000,000 Class A shares at $31.00 per share, expected to close on March 20, 2026. 4,980,000 shares are being sold by selling stockholders and 1,020,000 shares are a synthetic secondary to be repurchased by Guardian.
Underwriters have a 30‑day option for up to an additional 900,000 shares. Guardian will not retain net proceeds from selling stockholders and expects the repurchases to complete by March 24, 2026.
Guardian Pharmacy Services (NYSE: GRDN) launched a proposed underwritten public offering of 5,000,000 Class A shares on March 18, 2026, including 3,980,000 shares by selling stockholders and 1,020,000 newly issued shares by Guardian.
The underwriters have a 30-day option for up to an additional 750,000 shares. Guardian intends a non-dilutive "Synthetic Secondary": net proceeds it receives will be used to repurchase an equal number of Class A shares, keeping total outstanding Class A shares unchanged. A shelf registration on Form S-3 became effective November 3, 2025.
Guardian Pharmacy Services (NYSE: GRDN) reported Q4 2025 revenue of $397.6M (+17% YoY; organic +12%) and Q4 Adjusted EBITDA of $39.5M (+53% YoY). Full-year 2025 revenue was $1.45B (+18%); Adjusted EBITDA $115.1M (+27%); net income $49.0M versus a ($71.0M) loss in 2024. Cash totaled $65.6M at year-end. The company raised 2026 Adjusted EBITDA guidance to $120M–$124M while maintaining the prior 2026 revenue outlook of $1.40B–$1.42B. Operational highlights included one acquisition, improved vaccine profitability, and ~205,000 residents served at year-end.
Guardian Pharmacy Services (NYSE: GRDN) will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference.
CEO Fred Burke and CFO David Morris will take part in a fireside chat on Monday, March 16, 2026 at 10:40 a.m. ET. A live audio webcast and a replay available for 90 days will be hosted on the company investor site.